SSCrFCES is a biologically active, recombinant fragment of factor C, which is the endotoxin-sensitive serine protease of the LAL coagulation cascade. The ϳ38 kDa protein represents the LPS binding domain of factor C. A novel secretory signal directs the secretion of SSCrFCES into the culture supernatant of Drosophila cells, and hence it is readily purified. By differential ultrafiltration followed by preparative isoelectric membrane electrophoresis, SSCrFCES was purified as an isoelectrically homogeneous and stable monomeric protein 
Endotoxin, also known as lipopolysaccharide (LPS), is an integral component of the gram-negative bacterial cell membrane and is responsible for many, if not all, of the toxic effects that occur during gram-negative bacterial sepsis (1) . LPS is a mixture of glycolipids consisting of a variable polysaccharide domain covalently bound to a conserved glucosamine-based phospholipid known as lipid A. LPS directly stimulates host monocytes and macrophages to secrete a wide array of inflammatory cytokines that includes tumor necrosis factor ␣ (TNF-␣), interleukins-1 (IL-1), and interleukin-8 (IL-8) (2) . Excessive release of these cytokines by host macrophages almost assuredly contributes to organ failure and death that occur after episodes of gram-negative bacterial sepsis (3) . The proinflammatory bioactivities exhibited by LPS are known to reside in the lipid A (4) .
LPS from gram-negative bacteria induce the amoebocytes of horseshoe crabs to aggregate and degranulate. Presumably, LPS-induced coagulation cascade represents an important defense mechanism used by horseshoe crabs against invasion of gramnegative bacteria (5) . The amoebocyte lysate has been used for decades as a tool to detect trace concentrations of LPS in solution: Limulus amoebocyte lysate (LAL) test (6, 7) . The molecular mechanism of coagulation in horseshoe crab has been established and involves a protease cascade. This cascade is based on three kinds of serine protease zymogens-factor C, factor B, proclotting enzymeand one clottable protein, coagulogen (8) . Being the initial activator of the clotting cascade, factor C functions as a biosensor that responds to LPS. Since factor C can be activated by femtograms of LPS, it is conceivable that it has an LPS binding region that exhibits exceptional high affinity for LPS. Consequently, this LPS binding domain can be used to detect and remove pyrogenic contaminants in pharmaceutical products intended for parenteral administration as well as for in vivo immunohistochemical determination of endotoxin localization (9) .
Our laboratory has cloned the homologous factor C zymogen cDNAs from one of the four extant species of horseshoe crab, Carcinoscorpius rotundicauda (CrFC) (10) . Initial attempts to express CrFC and its truncated forms in Escherichia coli resulted in a nonactive enzyme (11) . Subsequently, CrFC was cloned and expressed in methylotropic yeast, Pichia pastoris. However, neither the native nor the Saccharomyces cerevisiae ␣ mating factor signal sequences were capable of directing secretion of this mosaic protein into the culture media for easier purification (12) . Furthermore, the full-length CrFC was enzymatically nonactive although it retains weak endotoxin binding properties (13) . Here, for the first time, we report the expression and secretion of a functional LPS binding domain of C. rotundicauda factor C (SSCrFCES) via a novel secretory signal. The secreted protein was purified to homogeneity and subjected to amino-terminal sequencing. The biological functions of the recombinant SSCrFCES were assessed by measuring the ability of the SSCrFCES to bind lipid A using an ELISA-based lipid A binding assay as well as surface plasmon resonance interaction. We measured the SSCrFCES-mediated inhibition of endotoxin-induced Limulus amoebocyte lysate coagulation with a sensitive LAL kinetic-QCL assay. The SSCrFCES protein was also tested for its ability to suppress LPS-induced cytokines (TNF-␣ and IL-8) production by THP-1 and normal human peripheral blood mononuclear cells (hPBMC). SSCrFCES is noncytotoxic and has a clearance rate of 4.7 ml/min. Finally, preliminary analysis shows that a low dose of SSCrFCES protein protects galactosamine-sensitized mice from LPS-induced lethality.
EXPERIMENTAL PROCEDURES Reagents
LPS from E. coli 055:B5 was purchased from Sigma (St. Louis, Mo.); lipid A from E. coli K12, D31me was purchased from List Biological Laboratories, Inc. (Campbell, Calif.) Drosophila Expression System and culture medium were obtained from InVitrogen (San Diego, Calif.). Rabbit polyclonal antiserum was raised against SSCrFCES and the anti-SSCrFCES Ig-G fraction was purified by affinity protein G-Sepharose FastFlow (Pharmacia; Piscataway, N.J.) according to manufacturer's specification. Limulus kinetic-QCL was obtained from BioWhittaker (Walkersville, Md.). Culture media for LPS-stimulation studies as well as insect cell-tested hygromycin were obtained from Life Technologies, Inc. (Gaithersburg, Md.). Low-endotoxin defined fetal bovine serum (FBS) was purchased from Hyclone (Logan, Utah). Phorbol myristate acetate (PMA) for activating THP cells and galactosamine were obtained from Sigma-Aldrich. Immunoassays for TNF-␣ and IL-8 were purchased from PharMingen (San Diego, Calif.). Cell Titer 96 AQueous for cytotoxic assay was from Promega (Madison, Wis.). EZ-Link PEO-maleimide activated biotein was purchased from Pierce (Rockford, Ill.). Oligonucleotides were synthesized by Genosys Biotechnologies, Inc. (The Woodlands, Tex.). Enzymes for DNA manipulation and polymerase reactions were purchased from NEB (Beverly, Mass.) and Boehringer Mannheim (Mannheim, Germany). DNA purification kits used were from Qiagen (Chatsworth, Calif.). Pyrogen-free water for making buffers was from Baxter (Morton Grove, Ill.).
Construction of a secreted LPS binding domain of C. rotundicauda factor C gene (SSCrFCES)
A novel secretory signal, SS (patent filed), was isolated via polymerase chain reaction (PCR) performed in a 100 l reaction using 100 ng of template DNA, 10 l of 10 ϫ Thermol buffer, 200 M each of dNTPs, 1 U of Vent R (exo-) polymerase, and 200 M of T3 forward primer (5Ј-ATTAAC-CCTCACTAAAGGGA-3Ј) and reverse primer (patent filed). The PCR cycles consisted of an initial denaturation at 94°C for 3 min, followed by 29 cycles of 94°C for 45 s, 52°C for 30 s, and 72°C for 30 s, with a final extension step at 72°C for 3 min. The PCR product was purified using Qiaquick PCR Purification Kit and subsequently digested with SacI. This 131 bp SS fragment was subcloned into pEGFP-N1 vector (Clontech; Palo Alto, Calif.) at the SacI and SmaI sites. To reduce the length of 5Ј UTR, the SS was digested with EcoRI and BglII, blunted with Klenow enzyme, and religated. The sequences at the junction were determined by Taqtrack Sequencing System (Promega) using EGFP-reverse primer (5Ј-CCCTCGCCGGACACGCTGA-3Ј). The modified vector containing the SS was designated pSSEGFP. The full-length CrFC was digested with BglII and NotI and subcloned into the BamHI and NotI of pSSEGFP. The LPS binding region of CrFC was released by Eco 47III and SalI and inserted into pAc5/V5-His Drosophila expression vector backbone. The vector coding for a secreted LPS binding domain of CrFC was designated pAc5/SSCrFCES-V5-His.
Stable expression of SSCrFCES in Drosophila S2 cells
To express SSCrFCES protein, the expression vector pAc5/ SSCrFCES-V5-His and selection vector, pCoHygro, were purified via EndoFree plasmid kits. The vectors were introduced into Drosophila S2 cells (14) by calcium phosphate coprecipitation method (15) . Drosophila S2 cells were routinely maintained in DES expression medium supplemented with 10% FBS. The cells were incubated at 25°C in a humidified incubator. For transfection, 3-6 ϫ 10 6 cells were introduced with 20 g of plasmid DNAs at a ratio of 19 SSCrFCES:1 pCoHygro. After transfection, cells were maintained in calcium phosphate solution for 24 h. Subsequently, cells were washed twice with complete medium to remove the calcium phosphate solution and allowed to recover for 2 days. Selection for stable cell lines was performed by the addition of 350 g/ml of insect cell-tested hygromycin (Life Technologies, Inc.) over a period of 3 wk. Stable cell lines expressing SSCrFCES were adapted to DES serum-free medium by weaning over three or four passages. To test for SSCrFCES expression, 30 l of medium was electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and proteins were electrophoretically transferred to PVDF membrane (Millipore; Bedford, Mass.). The recombinant SSCrFCES was detected using INDIA-HisProbe-HRP (Pierce) as described by the manufacturer.
TALON resin was thoroughly resuspended and 2 ml of homogeneous 50% suspension was packed by gravity in 10 ml disposable column. The resin was preequilibrated with binding buffer (20 mM NaH 2 PO 4 , 250 mM NaCl, and 4 M urea, pH 8.0). Typically, 300 ml of conditioned medium was desalted and concentrated sevenfold via ultrafiltration through a 10 kDa membrane. The concentrated medium was then adjusted to the same ionic strength as the binding buffer. The medium was applied to the packed resin. The filtrate was collected and reapplied to the column. The resin-protein complex was then washed with 20ϫ resin volume with wash buffer (20 mM NaH 2 PO 4 , 250 mM NaCl, and 8 M urea, pH 8.0). The SSCrFCES was eluted by adding three resin volumes of elution buffer (20 mM NaH 2 PO 4 , 250 mM NaCl, and 4 M urea, pH 5.0). The eluate was collected and concentrated using Microcon 10 (Millipore).
A 10% SDS-PAGE was cast and allowed to age overnight at 4°C. Prior to loading sample, the gel was pre-run in Trisglycine-SDS buffer for 15 min at constant 50 mA. Two micrograms of Cobalt-column purified SSCrFCES was loaded and electrophoresed. PVDF membrane (Millipore) was prewetted by brief immersion in 100% methanol, rinsed with Milli-Q water, and equilibrated in transfer buffer (10 nM CAPS, 10% methanol, pH 11.0) for a minimum of 15 min. After electrophoresis, the gel was soaked in transfer buffer for 5 min. The gel and treated PVDF membrane were sandwiched, and electroblotting was carried out at constant 50 V for exactly 50 min. After the transfer was completed, the membrane was rinsed several times in Milli-Q water. The SSCrFCES protein was visualized by staining in Coomassie blue R-250 for 5 min and destained with several changes of destaining solution (50% methanol, 10% acetic acid). The membrane was rinsed again with several changes of water, air-dried, and the SSCrFCES band was excised for aminoterminal amino acid sequencing. Protein sequencing was performed on ABI 477 sequencer.
Purification of SSCrFCES by preparative isoelectric membrane electrophoresis
Typically, two liters of conditioned medium were initially subjected to successive ultrafiltration using a 100 kDa and 10 kDa molecular mass cutoff with the Pellicon system (Millipore). The medium was concentrated sevenfold. The enriched SSCrFCES was purified to isoelectric homogeneity using preparative isoelectric membrane electrophoresis (Hoefer IsoPrime, Pharmacia). A set of four membranes with pHs of 6.5, 7.0, 7.25, and 7.5 was made. The concentration of acrylamido buffers used for the membranes was calculated based on information in Righetti and Giaffreda (16) . The four membranes were assembled in order, from acidic to basic, to delimit five chambers. Each sample reservoir vessel was filled with 30 ml of pyrogen-free water and pre-run at 4°C, 4 W constant power (3000 V limiting, 20 mA maximum) for 2 h. After removing the pre-run water, the protein sample was placed in sample reservoir vessel corresponding to the chamber delimited by pH 7.0 and 7.25. The IsoPrime was conducted under the same conditions for at least 48 h and the content from each chamber was analyzed on a 12% SDS-PAGE. Purified SSCrFCES was used for production of antiSSCrFCES antibody in rabbits.
ELISA-based lipid A binding assay
A Polysorp 96-well plate (Nunc) was first coated with 100 l per well of various concentrations of lipid A diluted in pyrogen-free phosphate-buffered saline (PBS). The plate was sealed and allowed to incubate overnight at room temperature. The wells were aspirated and washed six times with 200 l wash solution (PBS containing 0.01% Tween-20 and 0.01% thimerosal). Blocking of unoccupied sites was achieved using a wash solution containing 0.2% BSA for 1 h at room temperature. Subsequently, blocking solution was removed and the wells were washed as described above. Varying concentrations of SSCrFCES were allowed to interact with bound lipid A at room temperature for 2 h. Bound SSCrFCES was detected by sequential incubation with rabbit anti-SSCrF-CES antibody (1:1000 dilution) and goat anti-rabbit antibody conjugated with horseradish peroxidase (HRP) (1:2000 dilution) (Dako; Carpentia, Calif.). Each antibody incubation was for 1 h at 37°C with washing between incubations as described above. In the final step, 100 l of peroxide substrate ABTS (Boehringer Mannheim) was added. Using a microtiter plate reader, the absorbance of the samples was determined at 405 nm with reference wavelength at 490 nm. The values were correlated to the amount of LPS bound and SSCrFCES present. Quantitation of SSCrFCES was achieved from a standard curve derived by immobilizing known amount of purified SSCrFCES onto a Maxisorp plate. The detection was as described above.
Immobilization of lipid A and biospecific interaction with SSCrFCES
Recognition of lipid A by secreted SSCrFCES was determined by surface plasmon resonance (SPR), with BIAcore X biosensor instrument using HPA (hydrophobic adsorption) sensor chip. Briefly, lipid A at 0.5 mg/ml in PBS was immobilized to a HPA sensor chip (Pharmacia) according to the manufacturer's specification. In all experiments, pyrogen-free PBS was used as the running buffer at a flow rate of 10 l/min. Purified SSCrFCES at 4 g/ml was injected into the flow cell at a rate of 10 l/min, and the binding response was measured as a function of time. After injection of SSCrFCES, a solution of INDIA HisProbe-HRP, diluted in PBS to 400 g/ml, was also injected to cause a shift in response unit in order to further confirm that SSCrFCES binds to lipid A. For regeneration, the bound SSCrFCES was removed by injection of 100 mM of NaOH solution for 5 min.
Limulus kinetic-QCL for determining the ENC 50 of SSCrFCES
The Limulus kinetic-QCL is a quantitative, kinetic assay for the detection of gram-negative bacterial endotoxin. This assay uses the initial part of LAL endotoxin reaction to activate an enzyme, which in turn releases p-nitroaniline from a synthetic substrate, producing a yellow color. The time required before the appearance of a yellow color is inversely proportional to the amount of endotoxin present. Throughout the assay, the absorbance at 405 nm of each well of the microplate was monitored. Using the initial absorbance reading of each well as its own blank, the time required for the absorbance to increase 0.200 absorbance units was calculated as reaction time. The 50% endotoxin-neutralizing concentration (ENC 50 ) reflects the potency of SSCrFCES; a low ENC 50 indicates high potency.
Briefly, 25 l of endotoxin solution at 200 EU/ml was mixed with an equal volume of SSCrFCES at 1 M in a series of twofold dilutions in LAL reagent water in disposable endotoxin-free glass dilution tubes (BioWhittaker) and incubated at 37°C for 1 h. The reaction mixtures were each diluted 1000-fold with LAL reagent water. The endotoxin activity was then quantified with Limulus kinetic-QCL. One hundred microliters of the diluted test mixture was carefully dispensed into the appropriate wells of an endotoxin-free microtiter plate (Costar; Cambridge, Mass.).
The plate was then preincubated for Ͼ10 min in a temperaturecontrolled ELISA plate reader. Near the end of the preincubation period, 100 l of freshly reconstituted kinetic-QCL reagent was dispensed into the wells using an 8-channel multipipettor. The absorbance at 405 nm of each well of the microtiter plate was monitored at time intervals of 5 min over a period of 2 h. A 5 s automix was activated prior to reading. In the Limulus kinetic-QCL, the assay was activated by 0.005 EU/ml of endotoxin. The high sensitivity of the assay allowed for very low levels of endotoxin to be detected. After incubation of endotoxin with SSCrFCES, a 1000-fold dilution was introduced to eliminate any potential effects of the SSCrFCES on the LAL enzyme system. A sigmoid curve is usually expected between relative reaction time and the logarithmic concentration of the SSCrFCES. The best fit curve was derived using SigmaPlot and the concentration corresponding to 50% relative increase in reaction time was designated ENC 50 . The mean values were obtained from three independent experiments.
LPS stimulation of THP-1 and hPBMC
All cell lines were grown at 37°C in a humidified environment in the presence of 5% CO 2 . THP-1 cells were grown in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (0.1 mg/ml). The cells were maintained at a density between 2.5 ϫ 10 5 and 2.5 ϫ 10 6 cells/ml. THP-1 cells were prepared for experiment by addition of a concentrated stock solution of PMA (0.3 mg/ml in dimethyl sulfoxide) to cell suspension to give a final concentration of 30 ng/ml PMA and 0.01% dimethyl sulfoxide (17) . PMAtreated cell suspensions were immediately plated into 96-well microtiter plate at a density of 4 ϫ 10 5 cells/ml and allowed to differentiate for 48 h at 37°C. Immediately before stimulation by 25 ng/ml LPS or LPS preincubated with various concentrations of SSCrFCES, the culture medium was removed and the cells were washed twice with serum-free RPMI 1640, then incubated at 37°C. At indicated times, the culture medium was collected. Human TNF-␣ and IL-8 concentrations in the supernatants were assayed using ELISA as suggested by the manufacturer.
Heparinized venous blood drawn from healthy donors was subjected to fractionation using Ficoll-Paque PLUS (Pharmacia) to obtain peripheral blood mononuclear cells. PBMC were washed with PBS and suspended at a cell density of 1.5 ϫ 10 6 cell/ml with RPMI 1640 medium supplemented with 10% FBS. PBMC were incubated at 37°C for 24 h at a density of 1.5 ϫ 10 5 per well. LPS stimulation and immunoassay of hTNF-␣ and hIL-8 were performed as described for THP-1 cells. In addition, the suppressive effect of SSCrFCES on LPS-induced cytokine release was investigated in the presence of 10% human serum. The difference between the test and control groups was subjected to Student's t test. The values were obtained from at least three independent experiments.
Cytotoxicity of SSCrFCES in eukaryotic cells
2 ϫ 10 4 THP-1 monocytes in 50 l of RPMI 1640 were mixed in a microtiter plate with 50 l of an increasing amount of twofold serial dilutions of SSCrFCES (0.004 -4.0 mg/ml in PBS) and incubated for 60 min at 37°C. To determine cytotoxicity induced by the SSCrFCES, 20 l of CellTiter96 AQ ueous One Solution Reagent (Promega) was added into each well for 90 min at 37°C. [3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) is bioreduced by metabolically active cells into a colored formazan product that is soluble in tissue culture medium (18, 19) . For detection, the absorbance was measured at 490 nm. To determine the ratio of cell lysis induced by SSCrFCES, two controls were used. Complete lysis (100%) was achieved by incubating cells in PBS containing 0.2% Tween-20 instead of medium only. This absorbance value corresponded to the background, as those cells could not metabolize MTS. The second control representing 0% lysis was determined by incubating cells in medium only. The LD 50 was calculated as the concentration of SSCrFCES necessary to lyse 50% of the cells. The experiment was done in triplicate.
Biotin labeling SSCrFCES and pharmacokinetic analysis
600 micrograms of SSCrFCES was labeled with biotin using EZ-Link PEO-maleimide activated biotin (Pierce) according to the manufacturer's instructions. The excess biotin was subsequently removed via ultrafiltration through Micron-10 (Milipore). Three C57BL/6J mice were given a single intravenous (i.v.) bolus injection of 200 g biotin-labeled SSCrF-CES. Blood was collected in heparinized capillary tubes from each of the three mice over a 5 h period. The plasma was immediately treated with SDS-PAGE loading dye and boiled for 5 min. The mixture was resolved in a 12% SDS-PAGE and electroblotted onto a PVDF membrane. Immunoblotting and hybridization were carried out as described above except NeutrAvidin-HRP antibody (Pierce) was used. Exposure time for chemiluminescence detection was extended to 1 h. The signal on the X-ray film was quantitated via densitometric scan. The clearance rate of biotin-labeled SSCrFCES was analyzed using NCOMP, a Windows-based program for noncompartmental analysis of pharmacokinetic data (20) .
LPS-induced lethality in galactosamine-sensitized mice
Mice are typically resistant to endotoxin. However, the sensitivity of mice to endotoxin can be enhanced Ͼ 1000-fold by coinjection with a liver-specific inhibitor, galactosamine (21) . In our study, intraperitoneal (i.p.) injection of 2.5 ng of E. coli 055:B5 LPS together with 15 mg of galactosamine hydrochloride in 0.2 ml of saline induced nearly 100% lethality in 18 -25 g C57BL/6J mice within 7 h. Various concentrations of SSCrFCES (1, 2, and 4 M) were injected i.v. through tail vein 10 min after i.p. injection of the LPS-galactosamine mixture. Lethality was observed for 3 days after injection. Statistical analysis were performed using the Kaplan-Meier test (22) 
RESULTS

Expression and secretion of SSCrFCES in Drosophila insect cells
Transfection of S2 cells with SSCrFCES resulted in ϳ70% transformants. Stable recombinant Drosophila cell lines were obtained and the distribution of the protein was identified using chemiluminescent Western blot. SDS-PAGE analysis of Drosophila cells transformed with the recombinant vector is shown in Fig.  1A . The Western blot revealed the presence of a protein with an apparent molecular mass of ϳ38 kDa (Fig. 1B) . SSCrFCES in medium represented Ͼ 90% of the total recombinant protein expression. When stable cell line was cultured in serum-free medium without hygromycin for a week in a 1L-Bellco spinner flask, a typical yield ϳ1.6 mg/l of SSCrFCES was achieved.
The secretion of CrFCES is directed by a novel 15 residue hydrophobic secretory signal. The precise cleavage point at the SS adjoining the mature fusion CrFCES protein was determined by NH 2 -terminal amino acid sequencing of TALON column-purified SSCrFCES, which indicated that SS was efficiently and accurately cleaved at a single site in recombinant 
Purification of SSCrFCES using TALON column
Stable recombinant Drosophila cells secreting SSCrF-CES was grown in serum-free medium for easy purification. The medium was initially concentrated and desalted via three rounds of ultrafiltration using a 10 kDa cutoff membrane in an Amicon stirred cell (Millipore). Affinity chromatography purification under denaturing conditions yielded a ϳ38 kDa protein of interest in addition to a ϳ67 kDa contaminating protein. Thus, this larger protein is likely due to nonspecific adsorption to the resin. Several attempts to increase the purity of SSCrFCES by increasing the NaCl concentration from 250 mM to 300 -400 mM resulted in a drastic reduction in SSCrFCES yield. A compromise was arrived between yield and purity. The SSCrFCES protein represented ϳ85% of the total protein recovered. Consequently, prior to amino-terminal amino acid sequencing, the two proteins were resolved in a 10% SDS-PAGE. The ϳ38 kDa SSCrFCES protein band of interest was excised for amino-terminal amino acid sequencing after electrotransfer to a PVDF membrane.
Purification of SSCrFCES by preparative isoelectric membrane electrophoresis
An initial attempt using 10 kDa concentrated medium for ISOPrime resulted in the coprecipitation of SSCrFCES with minor high molecular weight proteins. Thus, an additional 100 kDa cutoff ultrafiltration was introduced that eliminated the coprecipitation problem. The 100 kDa and 10 kDa ultrafiltrated medium containing the protein was subsequently purified to homogeneity using PI 8 IsoPrime MultiChambered Isoelectric Focusing Unit. The pI of the SSCrFCES was determined to be 7.1 at 4°C. A Coomassie-stained SDS-PAGE of secreted SSCrFCES is shown in Fig. 1A . The relative ease with which SSCrFCES is purified to apparent homogeneity from the culture medium illustrates the advantage of using SS for the secretion and subsequent purification of heterologous proteins that are otherwise not efficiently purified from whole cell lysate. This method of purification yielded higher and purer SSCrFCES with intact biological activity. A) Coomassie brilliant blue-stained 12% reducing SDS-PAGE profile of crude and purified SSCrFCES. The recombinant protein, SSCrFCES, was effectively secreted into the culture medium of S2 cells and identified as a 38 kDa protein band. Affinity purification under denaturing conditions did not result in a pure SSCrFCES preparation. A ϳ67 kDa contaminant was copurified. Purification using ISOPrime resulted in an isoelectrically homogeneous SSCrF-CES. B) Immunoblotting analysis was performed with INDIA His-HRP antibody and visualized using SuperSignal Chemiluminescence. A specific 38 kDa band, in close agreement with calculated SSCrFCES size, was identified as the only secreted and purified protein harboring a poly-histidine tag. Exposure time, using Biomax film (Kodak), was limited to 5 s. Lanes are identified as follows: 1, low molecular weight marker (Pharmacia); 2, control medium (30 g); 3, crude SSCrFCES medium (30 g); 4, Affinity purified SSCrFCES (1 g); 5, ISOPrime-purified SSCrFCES (1 g)
One SSCrFCES molecule binds cooperatively to more than two molecules of lipid A
Results from the ELISA-based lipid A binding assay displayed a biphasic curve (Fig. 2A) . This usually indicates the presence of multiple binding sites for the ligand. SSCrFCES binds to lipid A with a stoichiometry of one SSCrFCES to two or three lipid A molecules at saturation (Fig. 2B ). This observation of the LPS binding domain of factor C interacting with two or three molecules of lipid A is novel. Scatchard plots of the binding data (not shown) are very convex, indicating that the binding of SSCrFCES to lipid A is highly cooperative. This is confirmed by the slope of the line obtained from plotting the data (Fig. 2C) according to the Hill's equation (23), which gave a coefficient of 2.2.
SPR studies of interactions between CrFCES and lipid A
The ability of SSCrFCES to bind LPS was also shown by SPR, using the BIAcore X (Fig. 3) . Injection of purified SSCrFCES (400 ng/100 l) over immobilized lipid A resulted in an increase of ϳ200 relative response unit. This represents a 92% saturation of lipid A. Subsequently, injection of antibody (INDIA His-HRP Ab) against the poly-His tag of SSCrFCES resulted in a further increase of relative response unit. The binding of INDIA His-HRP Ab to SSCrF-CES, which contains 6-His tag, further confirms that only SSCrFCES was bound to the immobilized lipid A. Surface plasmon resonance, in addition to INDIA His-HRP Ab, provided a faster way to assess both quantitatively and qualitatively the batch-to-batch variations in yield and potency of SSCrFCES.
Inhibition of endotoxin-induced LAL reaction
The 50% endotoxin-neutralizing concentration (ENC 50 ) value of SSCrFCES against 200 EU of endotoxin per milliliter (LPS, E. coli 055:B5) was determined using kinetic-QCL. The time that is required before the appearance of a yellow color (reaction time) is inversely proportional to the amount of endotoxin present. A low ENC 50 indicates high potency of endotoxin neutralization. The ENC 50 is taken as the concentration of SSCrFCES that reduces the mean reaction time by 50%. A sigmodal curve was obtained between relative reaction time and the logarithmic concentration of SSCrFCES (Fig. 4) . ENC 50 of SSCrFCES was determined to be 0.069 Ϯ 0.014 M. The low concentration of SSCrFCES required to achieved ENC 50 is not unexpected, since SSCrFCES is derived from the factor C serine protease that activates the LAL reaction.
SSCrFCES inhibits LPS-stimulated hTNF␣ and hIL-8 release from THP-1
Results from our in vitro binding studies suggested that SSCrFCES would be a potent inhibitor of the LPS activation of monocytes. To test this prediction, we measured the ability of SSCrFCES to inhibit hTNF-␣ and hIL-8 production by THP-1 cells incubated with 25 ng/ml and 100 ng/ml of LPS in a serum-free system containing various concentrations of SSCrFCES. As shown in Fig. 5 , 0.5 M of SSCrF-CES potently inhibited Ͼ90% LPS-induced production of TNF-␣ and IL-8 in the presence of 100 ng/ml of LPS. At the 25 ng/ml LPS concentration tested, 0.7 M of SSCrFCES is sufficient to completely prevent LPS-induced TNF-␣ production (Fig. 5A) . At 100 ng/ml LPS, 1 M of SSCrFCES reduced 90% IL-8 production as compared to control (Fig. 5B) .
SSCrFCES inhibits the production of TNF-␣ and IL-8 by human PBMC: effect of human serum on the anti-endotoxin potential of SSCrFCES
Purified human PBMC were used to test the suppression on endotoxin-induced TNF-␣ and IL-8 secretion by SSCrFCES under normal physiological conditions. In the absence of human serum, addition of only 0.1 M of SSCrFCES completely inhibited the TNF-␣ and IL-8 response to 10 ng/ml LPS by 50% (Fig. 6) . When SSCrFCES was added to human serum (final concentration, 10%) before the addition of endotoxin, the suppressive effect of SSCrF-CES was attenuated. It required 17-fold more SSCrF-CES to suppress TNF-␣ and IL-8 secretion by 50%. However, if the SSCrFCES was mixed with endotoxin 5 min before the addition of serum, the effect of the serum on the neutralization of endotoxin by SSCrF-CES was greatly reduced, requiring only fourfold more SSCrFCES for 50% inhibition (Fig. 6) .
Cytotoxicity of SSCrFCES to eukaryotic cells
The toxicity of SSCrFCES to mammalian cells was tested by incubation with human monocytes and analyzed using MTS, a compound that could only be metabolized by healthy cells. SSCrFCES had a mini- 
Pharmacokinetic analysis of biotin-labeled SSCrFCES in mice
Densitometric scan revealed that significant amounts of circulating half-life of SSCrFCES is sufficiently long to allow easy detection during the first 90 min postinjection. NCOMP, which provides an interactive graphical environment for noncompartmental analysis of pharmacokinetic data by facilitating estimation of the zero and first moments of concentration-time data, was used for analysis. The calculated clearance rate of biotin-labeled SSCrFCES in C57BL/6J mice is 4.7 ml/min.
Effects of SSCrFCES on endotoxin-induced lethality in galactosamine-sensitized mice
An i.p. injection of 2.5 ng of E. coli 055:B5 LPS per mouse induced 100% lethality in the galactosaminesensitized mice within 7 h. As shown in Fig. 7 , this LPS-induced lethality was reduced by 20% when 1 M of SSCrFCES was injected i.v. 10 min after the i.p. injection of LPS. Higher concentrations of SSCrFCES of 2 and 4 M conferred 90% and 100% protection, respectively. The data were analyzed using Kaplan-Meier analysis and log rank pairwise test. The protection was correlated with a reduction of the TNF-␣ level in mouse serum ( Table 1) .
DISCUSSION
Owing to its extreme sensitivity for endotoxin, factor C, a serine protease, plays an important role in pyrogen detection in pharmaceutical products. However, its LPS binding domain has never before been successfully expressed in a heterologous host to exhibit high affinity to LPS. The difficulty in doing so was largely due to its highly complex mosaic structure. While many highly disulfide-bonded proteins, like epidermal growth factor (24) and secreted acetylcholinesterase (25), were successfully expressed, few display the kind of complexity posed by the factor C LPS binding domain. The LPS binding property of factor C resides in the amino-terminal region spanning 333 amino acids. This short region constitutes a signal peptide, a cysteine-rich region, followed by epidermal growth factor-like domain, and finally three Sushi domains. High LPS affinity, comparable to the native factor C, requires the correct formation of 9 disulfide bonds (26) . This obstacle is compounded by the presence of a cysteine-rich region. Initial attempts to express and direct secretion of 943 amino acid NH 2 -end fragment in P. pastoris resulted in intracellular accumulation of the protein (12) . This intracellular recombinant protein was later shown to exhibit only weak Figure 5 . SSCrFCES inhibits LPS-induced A) hTNF-␣ and B) hIL-8 secretion from THP-1 in a dose-dependent manner. PMA-treated THP-1 cells were treated with both 25 ng/ml and 100 ng/ml of E. coli 055:B5 LPS, which were preincubated with varying concentrations of SSCrFCES. After 6 h of stimulation, the culture medium was assayed for TNF-␣ and IL-8. The decrease in TNF-␣ and IL-8 secretion were expressed as percentage of control (LPS only). Complete inhibition of TNF-␣ and 95% inhibition of IL-8 secretions were achieved using 1 M of SSCrFCES. Results are the means Ϯ sd of four independent experiments.
endotoxin binding capacity. It was speculated that either P. pastoris failed to fold the protein correctly or that the reducing environment of the cytosol is detrimental to the protein stability. Consequently, the LPS binding domain(s) was expressed in Drosophila S2 cells and directed secretion into the culture medium was achieved via a novel secretory signal, SS.
As starting material for purification work described in this study, we used a transfectant cell line that stably expresses and secretes recombinant SSCrFCES. We have developed two schemes to purify the SSCrFCES from the serum-free medium. The first scheme purifies SSCrFCES based on its carboxylterminal poly-His tag whereas the second scheme is based on its isoelectric value. To determine whether microheterogeneity exists during cleavage of SS, the first purification scheme was used. This allowed the purification of all recombinant proteins harboring the poly-His tag. The second scheme is unsuitable since it would result in the enrichment of a single isoform if present, and thus presents a biased interpretation. The SS is highly effective in directing secretion of SSCrFCES into the culture medium of Drosophila cells. Western analysis revealed the presence of a protein with an apparent molecular mass of ϳ38 kDa on SDS-PAGE. Practically all of SSCrFCES is secreted into the culture medium. The signal was cleaved at a single site as determined by aminoterminal amino acid sequencing, leaving behind six residues with SSCrFCES. Consequently, only a single species of SSCrFCES was expressed and accumulated in the medium. This is important for future crystallography studies. The six residues present in the mature SSCrFCES had no apparent influence on the LPS binding property of SSCrFCES.
Using the second purification scheme, the final SSCrFCES preparation is essentially an isoelectrically homogeneous protein species and is functional. The two key steps for the purification include 1) a concentration, desalting, and partial enrichment step using ultrafiltration through two molecular mass cutoff of 100 kDa and 10 kDa; and 2) preparative isoelectric membrane electrophoresis. The first step in purification uses tangential flow filtration technology and thus can be reliably scaled-up to industrial level. The second step can also be easily adapted to purify milligrams to grams of SSCrFCES. Recombinant SSCrFCES have been subjected to isoelectric focusing over a period of 3-4 days without detriment to the protein. The scheme reported here has been found to be reproducible in our laboratory throughout the course of more than 1 year. For the purification scheme, the overall recovery of SSCrFCES binding capacity is nearly 90%. This is attributable to its extreme stability conferred by the presence of 9 disulfide bonds. This report also presents, for the first time, the expression and secretion of a fully functional recombinant LPS binding domain of factor C, SSCrFCES. We provide evidence that the amino-terminal 333 amino acids of factor C are sufficient to mediate LPS binding capacity. The recombinant SSCrFCES, like other LPS binding proteins, binds to lipid A with high affinity. However, unlike other LPS binding proteins (27) (28) (29) (30) , SSCrFCES binds with a stoichiometry of one SSCrFCES molecule for two or three lipid A molecules at saturation. The binding is cooperative with a Hill's coefficient (23) of 2.2. This degree of cooperativity is comparable to hemoglobin for oxygen (31) and erythrocyte membrane tropomyosin for actin (32) . This phenomenon of multiple lipid A binding sites has hitherto not been documented to exist in any known LPS binding protein, with the exception of bactericidal/permeabilityincreasing protein (BPI) (27) . However, although BPI was reported to bind Ͼ one lipid A molecule, it was not reported to exhibit cooperativity in binding. This homotropic cooperativity for binding to lipid A is thus novel and unique to SSCrFCES. The presence of multiple lipid A binding sites that showed cooperativity assuredly confirm the LPS binding domain of factor C, as well as full-length factor C, to be the best candidate for removal and detection of endotoxin in solution. Cooperative binding also contributed to factor C's ability to detect subpicogram levels of endotoxin (unpublished data; patent filed) as well as a competitive binding advantage over Limulus anti-LPS binding factor (LALF). Retrospectively, the degranulation of amoebocytes in the presence of LPS would release a battery of anti-bacterial/LPS binding factors, e.g., LALF, thus significantly reducing the amount of free LPS. Nonetheless, factor C is capable of capturing trace LPS to activate the coagulation cascade. Such capability is attributed to its homotropic cooperativity as demonstrated by SSCrFCES, viz, its LPS binding domain. Kinetic-QCL, which uses the LAL reaction cascade, usually gives a good indication of the pyrogenicity of the LPS. Only a very low concentration of SSCrFCES (0.069 M Ϯ 0.014) is needed to achieve ENC 50 . Comparatively, this value is 28-and 7.5-fold less than ENC 50 of polymyxin B and LF-33 (33-mer peptide derived from lactoferrin) (33) , respectively. This shows that on a molar basis, much less SSCrFCES is required to neutralize the same amount of LPS. It also indicates that SSCrFCES is a potent anti-pyrogenic recombinant protein.
During gram-negative septicemia, the high concentration of LPS in the blood leads to multiple organ failure syndromes. These adverse effects are dependent on the generation of endogenous mediators. A multitude of mediators have been implicated, including arachidonic acid metabolites, PAF, cytokines such as TNF-␣, interferons, and various interleukins (e.g., IL-1, IL-8, etc.), reactive oxygen metabolites, and components of the coagulation cascade (1-3) . Consequently, the biological potential of SSCrFCES to bind and neutralize LPS-stimulated production of cytokines in human promonomyelocytic cell line THP-1 and normal human PBMC was investigated. Our findings indicate that 1 M of SSCrFCES effectively prevents the LPS-mediated induction of hTNF-␣ and hIL-8 production by THP-1 when these cells are incubated in the presence of high endotoxin levels. It is important to note that the concentrations of LPS (25 ng/ml and 100 ng/ml) used in these studies are among the highest known concentrations reported for LPS-induced cytokine production. On a molar basis, SSCrFCES appears to be more potent than polymyxin B and LF-33 at suppressing LPS-induced LAL coagulation and hTNF-␣ or hIL-8 secretion by THP-1 cells under serum-free conditions (33) . This suggests that SSCrF-CES has a much greater intrinsic capacity to neutralize endotoxin than polymyxin B. Again, it is attributable to its cooperative binding of LPS. Under serum free condition, a similar profile was observed when using human PBMC. In the presence of human serum, however, SSCrFCES anti-endotoxin potency was attenuated by 17-fold. A similar effect of human serum has also been observed with other cationic antiendotoxin proteins such as LF-33 (33) and LALF (34) . This is due to the interaction of these factors with serum proteins, which effectively reduces their availability for binding to endotoxin. Consistent with this explanation is our observation that mixing SSCrFCES with serum before endotoxin treatment reduces the ability of the SSCrFCES to suppress LPS-induced TNF-␣ and IL-8 secretion, requiring 17-fold more SSCrFCES to achieve 50% inhibition. This serum attenuating effect is greatly alleviated if SSCrFCES is incubated for 5 min with LPS prior to addition of serum.
In addition to high specific LPS binding, important features when using proteins for in vivo application to treat gram-negative bacterial septic shock are their physicochemical properties in biological systems. Problems that often arise in animal experiments are due to toxicity, as in the case of polymyxin B, or a short half-life in the circulating system-for example, BPI. To assess these features, we investigated SSCrFCES for their ability to permeabilize cultured cells. At the highest concentration of SSCrFCES tested (4 mg/ml), only 20% cell lysis was observed. This represented a 109-fold excess of SSCrFCES required for complete inhibition of cytokine secretion in THP-1 and PBMC cells. Comparatively, SSCrFCES is less cytotoxic than polymyxin B, where 50% cell lysis occurred with 0.51 mg/ml polymixin B (35) . The clearance rate of SSCrF-CES assessed via noncompartmental analysis was 4.7 ml/min. The disappearance of SSCrFCES from the circulation was 2.7-fold slower than BPI. Therefore, a lesser dose of SSCrFCES would be adequate to maintain high enough circulating levels to compete with LBP for LPS. It is conceivable that the clearance rate of SSCrFCES is significantly faster than LBP because SSCrFCES is an exogenously administered recombinant protein that is most likely metabolized faster in the liver.
Finally, the anti-endotoxin potency of SSCrFCES was also investigated in C57BL/6J mice. An i.p. injection of 2.5 ng of E. coli 055:B5 LPS into Dgalactosamine-sensitized C57BL/6J mice resulted in 100% lethality within 7 h. Whereas 1 M of SSCrF-CES was sufficient to completely neutralize the LPSinduced TNF-␣ and IL-8 secretion from THP-1 and human PBMC cells, it could reduce the lethality of mice by only 20% (Fig. 7) . Higher concentrations of SSCrFCES (2 and 4 M) conferred Ͼ90% survival. Two main factors are responsible for the requirement of this dose of SSCrFCES. First, SSCrFCES will have to compete with many serum proteins (e.g., LBP and albumin) for LPS. Second, the clearance rate of SSCrFCES with respect to LPS, is an important factor, as it determines the actual effective amount available for LPS binding. Nonetheless, i.v. injection of SSCrFCES in our experiments blocked the rise in cytokine levels, prevented liver damage, and thus significantly reduced LPS-mediated mortality (Table 1 ). Thus we show for the first time a protective role of SSCrFCES viz LPS binding domain of factor C in an i.p. murine sepsis model. The mechanism by which SSCrFCES protects mice from LPS-induced sepsis is presumably mediated through its high-affinity association with lipid A moiety of LPS, which consequently reduces the secretion of cytokines like TNF-␣ and IL-8.
In conclusion, this report presents for the first time the expression and localization of the functional LPS binding domain of factor C i.e., SSCrF-CES, which resides in the amino-terminal 333 amino acid. Two simple and rapid means of determining endotoxin binding were established: ELISA-based and BIAcore biomolecular interactions. The recombinant SSCrFCES has multiple lipid A binding sites and exhibits strong positive cooperativity. Furthermore, a low concentration of SSCrFCES is sufficient to completely inhibit the LPS-induced TNF-␣ and IL-8 secretion from THP-1 and PBMC cells. SSCrF-CES, being only weakly cytotoxic, can protect LPSinduced lethality in mice. This report also clearly explains the remarkable sensitivity of factor C for detection of trace endotoxin. Incidentally, the positive cooperativity of LPS binding is also responsible to the issue of linearity of LAL-based quantification of endotoxin. Additional investigations are also being carried out to determine whether singly or multiply bound lipid A are necessary to activate factor C. In view of the results presented here, recombinant factor C with enhanced sensitivity for LPS and better linear corelationship to endotoxin amount can be developed and would represent the next generation of endotoxin detection and quantification assay.
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